| Literature DB >> 35514899 |
Muhammad Ikhlas Abdjan1, Nanik Siti Aminah1,2, Imam Siswanto1, Tin Myo Thant3,4, Alfinda Novi Kristanti1,2, Yoshiaki Takaya5.
Abstract
A combination of computational techniques has been carried out to predict the binding of nordentatin derivatives based on pyranocoumarin semi-synthesis with the target protein from the expression of the PDE4B gene. The inhibition of the cAMP pathway is the main target of anti-cancer drugs, which is responsible for uncontrolled cell division in cancer. Modeling was done using a combination of semi-empirical methods and the density functional theory (PM3-DFT/6-31G*/B3LYP) to obtain the optimal structure of a small ligand that could be modeled. Studies on the interaction of the ligands and amino acid residues on protein targets were carried out using a combination of molecular docking and molecular dynamic simulation. Molecular docking based on functional grid scores showed a very good native ligand pose with an RMSD of 0.93 Å in determining the initial coordinates of the ligand-receptor interactions. Furthermore, the amino acid residues responsible for interaction through H-bonds were Tyr103, His104, His177, Met217, and Gln313. The binding free energy (kcal mol-1) results of the candidates were PS-1 (-36.84 ± 0.31), PS-2 (-35.34 ± 0.28), PS-3 (-26.65 ± 0.30), PS-5 (-42.66 ± 0.26), PS-7 (-35.33 ± 0.23), and PS-9 (-32.57 ± 0.20), which are smaller than that of the native ligand Z72 (-24.20 ± 0.19), and thus these have good potential as drugs that can inhibit the cAMP pathway. These results provide theoretical information for the efficient inhibition of the cAMP pathway in the future. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35514899 PMCID: PMC9058016 DOI: 10.1039/d0ra07838g
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
The structure of nordentatin derivatives
|
| |||||
|---|---|---|---|---|---|
| Candidates | R1 | R2 | R3 | R4 | R5 |
| PS-1 | –H | –CF3 | –H | –CF3 | –H |
| PS-2 | –H | –CF3 | –H | –H | –H |
| PS-3 | –H | –Br | –H | –H | –H |
| PS-4 | –H | –Cl | –F | –H | –H |
| PS-5 | –Cl | –H | –NO2 | –H | –H |
| PS-6 | –H | –H | –Br | –H | –H |
| PS-7 | –H | –C4H9 | –H | –H | –H |
| PS-8 | –Cl | –H | –H | –H | –H |
| PS-9 | –Cl | –H | –Cl | –H | –Cl |
Geometry optimization of the nordentatin derivatives using the PM3 semi-empirical and density functional theory with the basis set 6-31G*/B3LYP
| Candidates |
| Charge dis. (eV) |
| Molecular length (Å) |
|---|---|---|---|---|
| P | −1036.92 | −0.64 → 0.59 | 7.40 | 10.58 |
| PS-1 | −2055.39 | −0.57 → 0.80 | 5.77 | 15.15 |
| PS-2 | −1718.36 | −0.57 → 0.79 | 7.16 | 15.14 |
| PS-3 | −3952.42 | −0.57 → 0.60 | 7.24 | 14.39 |
| PS-4 | −1940.14 | −0.57 → 0.60 | 6.65 | 14.26 |
| PS-5 | −2045.40 | −0.54 → 0.60 | 5.51 | 15.13 |
| PS-6 | −3952.42 | −0.57 → 0.60 | 6.45 | 14.87 |
| PS-7 | −1538.58 | −0.57 → 0.59 | 7.65 | 18.02 |
| PS-8 | −1840.90 | −0.54 → 0.60 | 8.07 | 14.10 |
| PS-9 | −2760.08 | −0.55 → 0.60 | 7.16 | 14.49 |
Molecular docking validation of the native ligand
| Native ligand | RMSD (Å) | H-bond distance (Å) | Grid score (kcal mol−1) |
|---|---|---|---|
| Z72 | 0.93 | 2.11 (Gln313:HE22-Z72:O10) | −63.90 |
| 2.83 (Gln313:HE22-Z72:O3) |
Fig. 1Visualization of molecular docking validation: (A) cluster sphere selected; (B) the active site where the native ligand binds; (C) interaction between the native ligand and amino acid residues; (D) the types and 2D-diagram of the interactions.
Fig. 2Visualization of the pocket area of the active site: Z72 (dim gray), candidates (cornflower blue), and amino acid residues in a radius of 4 Å (gray).
Molecular docking results of the candidates on the receptor
| Candidate ligands | Grid score (kcal mol−1) |
|
|
|
|---|---|---|---|---|
| P | −51.60 | −45.52 | −6.08 | 17.06 |
| PS-1 | −69.95 | −67.18 | −2.77 | 34.06 |
| PS-2 | −67.40 | −64.79 | −2.61 | 38.88 |
| PS-3 | −64.53 | −62.03 | −2.50 | 20.92 |
| PS-4 | −63.16 | −62.02 | −1.14 | 20.96 |
| PS-5 | −68.48 | −66.14 | −2.33 | 38.50 |
| PS-6 | −63.58 | −61.61 | −1.97 | 29.18 |
| PS-7 | −70.81 | −70.06 | −0.75 | 21.77 |
| PS-8 | −61.61 | −58.77 | −2.83 | 26.15 |
| PS-9 | −66.60 | −65.27 | −1.33 | 21.89 |
Fig. 3System stability during the simulation time of 120 ns: (A) output file analysis for total energy; (B) trajectory analysis of the root-mean-square displacement of the complexes.
Fig. 4Trajectory analysis during simulation over the last 20 ns: fluctuations in the (A) root-mean-square values and (B) radii of gyration of the complexes.
Fig. 5Solvent-accessible surface area (SASA): (A) all surface areas and (B) active-site surface areas of the complexes.
The average values of SASA: all surface areas and active-site surface areas of the complexes
| Candidate ligands | Average of SASA (Å) | |
|---|---|---|
| All surface areas | Active site | |
| Z72 | 18 490.63 ± 310.11 | 752.12 ± 56.23 |
| PS-1 | 17 932.83 ± 293.98 | 612.20 ± 44.73 |
| PS-2 | 18 377.30 ± 317.14 | 668.03 ± 55.49 |
| PS-3 | 19 420.68 ± 312.39 | 658.13 ± 51.06 |
| PS-5 | 17 919.90 ± 300.25 | 202.63 ± 37.64 |
| PS-7 | 18 032.12 ± 330.13 | 489.92 ± 59.43 |
| PS-9 | 18 111.43 ± 260.49 | 660.57 ± 47.99 |
Determination of energy components using the MM-GBSA approach. Data are shown as mean ± standard error of mean (SEM)
| Ligand | Δ | Δ | Δ |
|
|
|
|
|---|---|---|---|---|---|---|---|
| Z72 | −24.20 ± 0.19 | −30.64 ± 0.28 | 6.43 ± 0.23 | −32.75 ± 0.20 | 2.10 ± 0.28 | 10.12 ± 0.23 | −3.69 ± 0.02 |
| PS-1 | −36.84 ± 0.31 | −58.53 ± 0.43 | 21.69 ± 0.24 | −47.66 ± 0.30 | −10.87 ± 0.27 | 27.65 ± 0.25 | −5.96 ± 0.03 |
| PS-2 | −35.34 ± 0.28 | −60.70 ± 0.55 | 25.35 ± 0.44 | −45.34 ± 0.27 | −15.35 ± 0.50 | 31.62 ± 0.45 | −6.26 ± 0.02 |
| PS-3 | −26.65 ± 0.30 | −32.47 ± 0.46 | 5.82 ± 0.30 | −36.51 ± 0.32 | 4.03 ± 0.30 | 10.37 ± 0.31 | −4.55 ± 0.03 |
| PS-5 | −42.66 ± 0.26 | −73.97 ± 0.56 | 31.31 ± 0.44 | −59.44 ± 0.28 | −14.53 ± 0.58 | 38.82 ± 0.44 | −7.51 ± 0.02 |
| PS-7 | −35.33 ± 0.23 | −63.53 ± 0.31 | 28.19 ± 0.20 | −45.25 ± 0.26 | −18.27 ± 0.20 | 34.17 ± 0.21 | −5.97 ± 0.03 |
| PS-9 | −32.57 ± 0.20 | −49.48 ± 0.26 | 16.91 ± 0.19 | −40.40 ± 0.21 | −9.08 ± 0.23 | 21.24 ± 0.18 | −4.32 ± 0.02 |
Simulation of H-bond strength between the ligands and amino acid residues
| Ligand | Frames | Fraction (%) | H-bond | Distance (Å) | ||
|---|---|---|---|---|---|---|
| Acceptor | Donor (H) | MDS | MD | |||
| Z72 | 1716 | 13.41 | Z72_358:O10 | GLN_313:NE2 (HE22) | 2.99 | 2.11 |
| 743 | 5.80 | Z72_358:O3 | GLN_313:NE2 (HE22) | 3.15 | 2.83 | |
| PS-1 | 306 | 2.39 | PS1_358:F5 | GLN_313:NE2 (HE22) | 3.22 | ND |
| 9 | 0.07 | PS1_358:F2 | GLN_313:NE2 (HE21) | 3.25 | 2.50 | |
| 1 | 0.01 | PS1_358:F2 | GLN_313:NE2 (HE22) | 3.05 | 2.26 | |
| 1 | 0.01 | PS1_358:F6 | TYR_103:OH (HH) | 3.41 | 2.42 | |
| PS-2 | 5410 | 42.27 | PS2_358:O3 | GLN_313:NE2 (HE22) | 2.98 | 2.44 |
| 411 | 3.21 | PS2_358:F3 | MET_217:N (H) | 3.16 | 2.39 | |
| PS-3 | 4908 | 38.34 | PS3_358:O3 | GLN_313:NE2 (HE22) | 2.96 | 2.38 |
| PS-5 | 621 | 4.85 | PS5_358:O6 | GLN_313:NE2 (HE22) | 3.00 | 2.23 |
| PS-7 | 93 | 0.73 | PS7_358:O5 | HIE_104:NE2 (HE2) | 3.01 | 2.31 |
| ND | ND | PS7_358:O3 | HIE_177:NE2 (HE2) | ND | 3.01 | |
| PS-9 | 2.37 | 1.85 | PS9_358:O1 | HIE_104:NE2 (HE2) | 3.05 | ND |
Molecular dynamic simulation.
Molecular docking.
Non-detected.
Drug-likeness: physicochemical properties, Lipinski's rule of five and Veber's rule
| Code | Physicochemical properties | Lipinski's rule | Veber's rule | Lipinski and Veber validations/ | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| log | log | Fraction Csp3 |
| MW (Da) | ∑HBD | ∑O + N | Rotatable bonds | TPSA (Å2) | ||
| PS-1 | 7.96 | −8.12 | 0.29 | 5.37 | 552.46 | 0 | 5 | 7 | 65.74 | 2 |
| PS-2 | 7.07 | −7.24 | 0.26 | 4.89 | 484.46 | 0 | 5 | 6 | 65.74 | 1 |
| PS-3 | 6.88 | −7.29 | 0.23 | 4.97 | 495.36 | 0 | 5 | 5 | 65.74 | 1 |
| PS-5 | 6.65 | −7.05 | 0.23 | 3.95 | 495.91 | 0 | 8 | 6 | 111.56 | 0 |
| PS-7 | 8.07 | −7.66 | 0.33 | 5.18 | 472.57 | 0 | 5 | 8 | 65.74 | 1 |
| PS-9 | 8.07 | −8.17 | 0.23 | 5.80 | 519.80 | 0 | 5 | 5 | 65.74 | 2 |